INCLINE VILLAGE, Nev. , Nov. 22, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes due December 1, 2021 (2021 Notes).  PDL issued $150.0 million aggregate principal amount of 2021

INCLINE VILLAGE, Nev. , Nov. 22, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the 28 th Annual Piper Jaffray Healthcare Conference next week in New York .

INCLINE VILLAGE, Nev. , Nov. 17, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) announced today that it has agreed to sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 (the Notes) in an underwritten public offering.  The conversion rate

INCLINE VILLAGE, Nev. , Nov. 15, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) announced today that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes due December 1, 2021 (the Notes) under PDL's

INCLINE VILLAGE, Nev. , Nov. 3, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) ( NASDAQ : PDLI) today reported financial results for the third quarter ended September 30, 2016 including: Total revenues of $53.6 million and $177.8 million for the three and nine months ended September

INCLINE VILLAGE, Nev. , Oct. 27, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) ( NASDAQ : PDLI) today announced that the Company will release its third quarter 2016 financial results for the period ended September 30, 2016 , on Thursday, November 3, 2016 , after market close.

INCLINE VILLAGE, Nev. , Aug. 29, 2016 /PRNewswire/ --  PDL BioPharma, Inc. ( NASDAQ : PDLI) (PDL or the Company) today announced that PDL has received approximately $57.4 million in connection with the termination of PDL's credit agreement with Paradigm Spine, LLC , which included a repayment of

INCLINE VILLAGE, Nev. , Aug. 4, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) ( NASDAQ : PDLI) today reported financial results for the second quarter ended June 30, 2016 including: Total revenues of $21.0 million and $124.2 million for the three and six months ended June 30, 2016

INCLINE VILLAGE, Nev. , Aug. 4, 2016 /PRNewswire/ --  PDL BioPharma, Inc. ( NASDAQ : PDLI) (PDL or the Company) today announced that its board of directors has decided to eliminate its quarterly cash dividend. John P. McLaughlin , president and chief executive officer of PDL, stated, "Since 2009,

INCLINE VILLAGE, Nev. , Aug. 1, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) ( NASDAQ : PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) ( NASDAQ : ARIA) which was due on the first anniversary of the closing date

INCLINE VILLAGE, Nev. , July 28, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) ( NASDAQ : PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016 , on Thursday, August 4, 2016 , after market close.

--Webcast Conference Call Scheduled for Today at 4:30 p.m. EDT--

INCLINE VILLAGE, Nev. , June 13, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL or the Company) ( NASDAQ : PDLI) today announced that it has paid the June 13, 2016 , quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of June 6, 2016 , the record date.

INCLINE VILLAGE, Nev. , June 1, 2016 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) ( NASDAQ : PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York .

--Transaction Represents First Specialty Pharmaceutical Transaction by PDL--
--Upon Close, Transaction Expected to be Immediately Accretive--